Actively Recruiting
Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma
Led by The Affiliated Hospital of Xuzhou Medical University · Updated on 2021-07-20
20
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
Sponsors
T
The Affiliated Hospital of Xuzhou Medical University
Lead Sponsor
X
Xuzhou Medical University
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is an experimental study to evaluate the safety and efficacy of CAR T cells targeting CAIX in the treatment of advanced renal cancer.
CONDITIONS
Official Title
Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female patients aged from 18 to 70 years old
- ECOG performance status score of 2 or less
- Advanced or metastatic renal cell carcinoma with prior first-line and second-line targeted therapy
- Prior immunotherapy with PD-1/L1 and two or fewer regimens
- Unable to tolerate targeted therapy or immunotherapy
- Measurable or evaluable lesions present
- Adequate liver function with ALT/AST less than 3 times the upper limit of normal
- Kidney function with creatinine less than 220 bcmol/L
- Lung function with oxygen saturation of 95% or higher
- Cardiac function with left ventricular ejection fraction 40% or higher
- Voluntary participation with signed informed consent
You will not qualify if you...
- Infectious diseases such as HIV, active hepatitis B or C, or active tuberculosis
- Insufficient transfection (<10%) or poor amplification (<5 times) of targeted lymphocytes
- Abnormal vital signs preventing cooperation with examinations
- Mental or psychological disorders preventing cooperation with treatment or evaluations
- Severe allergies, especially to IL-2
- Systemic or severe local infections requiring anti-infection treatment
- Dysfunction of major organs including heart, lung, brain, liver, or kidney
- Presence of other tumors
- Any other medical reasons deemed by doctors to prevent inclusion in treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China, 221000
Actively Recruiting
Research Team
H
Hailong Li, M.D/Ph.D
CONTACT
Q
Qing Zhang, Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here